These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 24517955)

  • 1. Speed of Accrual Into Phase III Oncology Trials: A Comparison Across Geographic Locations.
    Ruther NR; Mathiason MA; Wee SK; Emmel AE; Go RS
    Am J Clin Oncol; 2015 Dec; 38(6):575-82. PubMed ID: 24517955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Time to activate lung cancer clinical trials and patient enrollment: a representative comparison study between two academic centers across the atlantic.
    Wang-Gillam A; Williams K; Novello S; Gao F; Scagliotti GV; Govindan R
    J Clin Oncol; 2010 Aug; 28(24):3803-7. PubMed ID: 20644091
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of Industry and Academic Sponsorship With Negative Phase 3 Oncology Trials and Reported Outcomes on Participant Survival: A Pooled Analysis.
    Addeo A; Weiss GJ; Gyawali B
    JAMA Netw Open; 2019 May; 2(5):e193684. PubMed ID: 31074821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The influence of industry sponsorship on the reporting of subgroup analyses within phase III randomised controlled trials in gastrointestinal oncology.
    Barton S; Peckitt C; Sclafani F; Cunningham D; Chau I
    Eur J Cancer; 2015 Dec; 51(18):2732-9. PubMed ID: 26608121
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The clinical development of molecularly targeted agents in combination with radiation therapy: a pharmaceutical perspective.
    Ataman OU; Sambrook SJ; Wilks C; Lloyd A; Taylor AE; Wedge SR
    Int J Radiat Oncol Biol Phys; 2012 Nov; 84(4):e447-54. PubMed ID: 22819210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preliminary evaluation of factors associated with premature trial closure and feasibility of accrual benchmarks in phase III oncology trials.
    Schroen AT; Petroni GR; Wang H; Gray R; Wang XF; Cronin W; Sargent DJ; Benedetti J; Wickerham DL; Djulbegovic B; Slingluff CL
    Clin Trials; 2010 Aug; 7(4):312-21. PubMed ID: 20595245
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How sociodemographics, presence of oncology specialists, and hospital cancer programs affect accrual to cancer treatment trials.
    Sateren WB; Trimble EL; Abrams J; Brawley O; Breen N; Ford L; McCabe M; Kaplan R; Smith M; Ungerleider R; Christian MC
    J Clin Oncol; 2002 Apr; 20(8):2109-17. PubMed ID: 11956272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Publication status of contemporary oncology randomised controlled trials worldwide.
    Chen YP; Liu X; Lv JW; Li WF; Zhang Y; Guo Y; Lin AH; Sun Y; Mao YP; Ma J
    Eur J Cancer; 2016 Oct; 66():17-25. PubMed ID: 27522246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Attractiveness of France for international clinical trials in 2012: 6(th) survey assessed by Leem (French association of pharmaceutical companies)].
    Lassale C; Sibenaler C; Béhier JM; Barthélémy P; Plétan Y; Courcier S
    Therapie; 2013; 68(1):1-18. PubMed ID: 23484655
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Industry-sponsored clinical research outside high-income countries: an empirical analysis of registered clinical trials from 2006 to 2013.
    Murthy S; Mandl KD; Bourgeois FT
    Health Res Policy Syst; 2015 Jun; 13():28. PubMed ID: 26041551
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use and reporting of patient-reported outcomes in phase III breast cancer trials.
    Brim RL; Pearson SD
    Clin Trials; 2013 Apr; 10(2):243-9. PubMed ID: 23539108
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Accrual to National Cancer Institute-sponsored non-small-cell lung cancer trials: insights and contributions from the CCOP program.
    Lyss AP; Lilenbaum RC
    Clin Lung Cancer; 2009 Nov; 10(6):410-3. PubMed ID: 19900858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Challenges to accrual predictions to phase III cancer clinical trials: a survey of study chairs and lead statisticians of 248 NCI-sponsored trials.
    Schroen AT; Petroni GR; Wang H; Thielen MJ; Sargent D; Benedetti JK; Cronin WM; Wickerham DL; Wang XF; Gray R; Cohn WF; Slingluff CL; Djulbegovic B
    Clin Trials; 2011 Oct; 8(5):591-600. PubMed ID: 21878447
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interventional oncology research in the United States: slowing growth, limited focus, and a low level of funding.
    Chow DS; Itagaki MW
    Radiology; 2010 Nov; 257(2):410-7. PubMed ID: 20829537
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thymitaq (Zarix).
    Niculescu-Duvaz I
    Curr Opin Investig Drugs; 2001 May; 2(5):693-705. PubMed ID: 11569949
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Accrual experience of National Cancer Institute Cooperative Group phase III trials activated from 2000 to 2007.
    Korn EL; Freidlin B; Mooney M; Abrams JS
    J Clin Oncol; 2010 Dec; 28(35):5197-201. PubMed ID: 21060029
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sponsorship of oncology clinical trials in the United States according to age of eligibility.
    Neel DV; Shulman DS; Ma C; Bourgeois F; DuBois SG
    Cancer Med; 2020 Jul; 9(13):4495-4500. PubMed ID: 32351000
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence and factors associated with use of placebo control groups in randomized controlled trials in psoriasis: a cross-sectional study.
    Katz KA; Karlawish JH; Chiang DS; Bognet RA; Propert KJ; Margolis DJ
    J Am Acad Dermatol; 2006 Nov; 55(5):814-22. PubMed ID: 17052487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Self-reported conflicts of interest of authors, trial sponsorship, and the interpretation of editorials and related phase III trials in oncology.
    Bariani GM; de Celis Ferrari AC; Hoff PM; Krzyzanowska MK; Riechelmann RP
    J Clin Oncol; 2013 Jun; 31(18):2289-95. PubMed ID: 23630201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Achieving sufficient accrual to address the primary endpoint in phase III clinical trials from U.S. Cooperative Oncology Groups.
    Schroen AT; Petroni GR; Wang H; Thielen MJ; Gray R; Benedetti J; Wang XF; Sargent DJ; Wickerham DL; Cronin W; Djulbegovic B; Slingluff CL
    Clin Cancer Res; 2012 Jan; 18(1):256-62. PubMed ID: 21976533
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.